The Future Value of TLT.vIMO the future value of Theralase is in their patents for XPDT and Immunotherapy.
And their targetting drug Rutherrin.
It can target and destroy deep seated tumours but avoid healthy cells.
Xrays or radiation of low intensity will trigger the absorbed Rutherrin in cancer cells to react and kill or damage the cells. Damaged cancer cells then alert an immune response which finishes the job anywhere in the body.